The current sales price of one unit of bimekizumab

Bimekizumab is a targeted immunotherapy drug, mainly used to treat inflammatory diseases caused by immune system abnormalities, such as plaque psoriasis. This drug plays an anti-inflammatory and immunomodulatory role by precisely inhibiting IL-17A and IL-17F, two cytokines, and has become an important treatment option in the field of dermatology.

In China, although bicizumab has been officially launched, it is not yet included in medical insurance, resulting in a relatively high price. Taking the packaging specification of 160mg*1 tube as an example, the domestic selling price is about RMB 3 to 4,000. However, due to the limited market supply of bicizumab and low inventory in some regions, patients may face longer waiting times and may even have difficulty purchasing the drug. Therefore, patients need to confirm the availability of drugs with their doctor or drug supplier before purchasing.

The selling price of Bicizumab in overseas markets is much higher than the domestic price. For example, in overseas markets, the price of 160mg*2 vials of original medicine is about RMB 40,000 to RMB 50,000, and the price may vary due to exchange rate fluctuations. It should be noted that there are currently no generic drugs of bichizumab on the market. Therefore, if patients want to purchase it through overseas channels, they need to bear the corresponding high costs.

For patients who need to purchase, considering that the price of the drug is relatively expensive, it is recommended to purchase through formal channels and understand possible international transportation and customs fees. At the same time, patients can also discuss with their doctors whether there are more economical treatment alternatives to control costs during the treatment process.

In general, bichizumab is a relatively expensive treatment drug, especially when it is not covered by domestic medical insurance. Patients need to make a reasonable choice based on their economic status and treatment needs.

Reference materials:https://www.drugs.com/bimekizumab.html